AMTX

Stifel Maintains Aemetis (AMTX) Buy Recommendation

Fintel reports that on July 7, 2023, Stifel maintained coverage of Aemetis (NASDAQ:AMTX) with a Buy recommendation.

Analyst Price Forecast Suggests 41.75% Upside

As of July 6, 2023, the average one-year price target for Aemetis is 9.91. The forecasts range from a low of 2.02 to a high of $29.40. The average price target represents an increase of 41.75% from its latest reported closing price of 6.99.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Aemetis is 374MM, an increase of 81.04%. The projected annual non-GAAP EPS is -0.37.

What is the Fund Sentiment?

There are 173 funds or institutions reporting positions in Aemetis. This is a decrease of 14 owner(s) or 7.49% in the last quarter. Average portfolio weight of all funds dedicated to AMTX is 0.01%, a decrease of 37.48%. Total shares owned by institutions decreased in the last three months by 8.82% to 16,930K shares. AMTX / Aemetis Inc Put/Call Ratios The put/call ratio of AMTX is 0.44, indicating a bullish outlook.

What are Other Shareholders Doing?

AMTX / Aemetis Inc Shares Held by Institutions

Grantham, Mayo, Van Otterloo & Co. holds 2,137K shares representing 5.82% ownership of the company. In it's prior filing, the firm reported owning 2,043K shares, representing an increase of 4.36%. The firm decreased its portfolio allocation in AMTX by 41.51% over the last quarter.

Encompass Capital Advisors holds 1,811K shares representing 4.94% ownership of the company. In it's prior filing, the firm reported owning 1,779K shares, representing an increase of 1.77%. The firm decreased its portfolio allocation in AMTX by 24.06% over the last quarter.

Alliancebernstein holds 1,254K shares representing 3.42% ownership of the company. In it's prior filing, the firm reported owning 1,718K shares, representing a decrease of 36.95%. The firm decreased its portfolio allocation in AMTX by 59.27% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,112K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 924K shares, representing an increase of 16.90%. The firm decreased its portfolio allocation in AMTX by 34.90% over the last quarter.

GOFIX - GMO Resources Fund Class III holds 765K shares representing 2.09% ownership of the company. In it's prior filing, the firm reported owning 994K shares, representing a decrease of 29.83%. The firm decreased its portfolio allocation in AMTX by 31.89% over the last quarter.

Aemetis Background Information
(This description is provided by the company.)

Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and bioproducts company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products. Founded in 2006, Aemetis has completed Phase 1 and is expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas (RNG). Aemetis owns and operates a 65 million gallon per year ethanol production facility in California's Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis also owns and operates a 50 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing the Carbon Zero biorefinery in Riverbank, California to convert renewable hydrogen from waste orchard wood and renewable electricity from solar and hydroelectric sources combined with non-edible oils into renewable jet fuel and renewable diesel, while pre-extracting cellulosic sugars for use by the Keyes ethanol plant to produce cellulosic ethanol. Aemetis holds a portfolio of patents and related technology licenses for the production of renewable fuels and bioproducts.

Additional reading:

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.